UBS/CALL/MODERNA/180.001/0.1/20.12.24 Stock

Warrant

UNBSWU

CH1348550224

Real-time Bid/Ask 10:35:15 2024-07-11 am EDT
0.45 ^CHF / 0.47 ^CHF	+35.29%

Current month	-10.53%
1 month	-71.67%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart MODERNA, INC.

Chart UBS/CALL/MODERNA/180.001/0.1/20.12.24

Latest news about MODERNA, INC.

Flagship Pioneering Expands Leadership Team with Key Appointments and Promotions	10:08am	AQ
Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024	10:08am	AQ
Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations that Transform Human Health and Sustainability	10:07am	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA	06:13pm	PR

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	MODERNA, INC.
Issuer	UBS
	UNBSWU
ISIN	CH1348550224
Date issued	2024-05-22
Strike	180 $
Maturity	2024-12-20 (162 Days)
Parity	10 : 1
Emission price	1.02 CHF
Emission volume	N/A
Settlement	cash
Currency	CHF

Technical Indicators

Highest since issue	2.13 CHF
Lowest since issue	0.34 CHF
Spread	0.02 CHF
Spread %	4.26%

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

More about the company